Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Duitse aandelen  /  Bayer 2022 Jaardraadje!

Ontvang nu dagelijks onze kooptips!

word abonnee

Duitse aandelen« Terug naar discussie overzicht

Bayer 2022 Jaardraadje!

475 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 24 »» | Laatste | Omlaag ↓
  3. forum rang 7 LL 11 februari 2022 11:37
    EXCLUSIVE-Bayer revives plan to introduce new GM cotton seeds in India

    NEW DELHI, Feb 10 (Reuters) - Germany's Bayer BAYGn.DE has applied to cultivate its next generation of genetically modified (GM) cotton seeds in India, government sources said, reviving plans to bring the high-yielding, herbicide-tolerant variety to the country.

    In late 2016, Monsanto withdrew an application seeking approval from New Delhi for the GM variety Bollgard II Roundup Ready Flex (RRF), to protest a raft of government measures against the world's biggest seed maker.

    Bayer, which bought Monsanto in 2018 for $63 billion, has resubmitted the application for Bollgard II RRF, signalling reviving interest from foreign seed, agricultural chemicals and farm technology companies in India, the world's leading producer of cotton, rice, wheat and an array of other farm goods.

    After Monsanto's row with India over pricing and intellectual property rights, other global corporations in the agriculture industry decided to scale back investments and put off plans to introduce new seed varieties and farming technologies in India.

    Bayer resubmitted the application seeking cultivation of the Bollgard II RRF variety in December, said the sources, who asked not to be identified in line with official rules.

    "Bayer, through its local joint venture partner, has resubmitted the dossier for seeking regulatory approvals to introduce RRF in India," said one of the government sources familiar with the matter.

    "Once the regulatory approval process starts, it might take a few years for Bayer to get the final approval."

    It was not clear when the approval process would start, the sources said.

    "Our efforts are aimed at enhancing crop productivity, contributing towards doubling farmer incomes and making Indian agriculture sustainable and globally competitive," Bayer said in an emailed statement to Reuters.

    The GM cotton seed variety could cut the cost of cultivation in India, boost crop yields and act as an antidote to the pink bollworm pest, farm policy experts said.

    The pink bollworm pest has of late become a major threat to India's cotton crop. The pest attack has also hit farmers' income, with nearly 20% to 30% of the country's 12 to 13 million hectares of the cotton area infested with pink ballworm, based on estimates from industry bodies and farmers.

    DATED TECHNOLOGY

    India first allowed GM cotton cultivation in 2002 by approving Monsanto's single gene Bollgard I technology, and Monsanto's GM cotton seed technology soon dominated 90% of India's cotton acreage. Apart from GM cotton, India has not approved any other transgenic crop.

    New Delhi approved Monsanto's double gene Bollgard II in 2006, helping to transform India into the world's No.1 cotton producer and second-largest exporter of the fibre as output jumped fourfold. India had previously been a net importer of cotton.

    But crop yields have stagnated since then and farmers say the existing variety is losing its effectiveness and becoming more vulnerable to pests such as pink bollworm.

    "In the absence of a new variety, Indian farmers are forced to rely on a dated technology," the head of a global seed company said requesting anonymity.

    "While India has dragged its feet, other producers have adopted newer cotton seed technologies over the past 15 years."

    The other major attraction for farmers is the convenience of weed management, said Bhagirath Choudhary, director of the South Asia Biotech Centre, an organisation for the promotion of biotechnology. Asia Biotech Society lists many government-run scientific research bodies and private companies, including Bayer as its research partners.

    "The RRF variety can significantly bring down the cost of cultivation for millions of India's poor, small farmers as the cost of labour for removing unwanted vegetation and picking weeds alone accounts for 65% of the total cost of cotton cultivation in the country," Choudhary said.
  12. forum rang 7 LL 18 februari 2022 09:45
    Bayer lifts peak sales estimate for prostate cancer drug

    By Ludwig Burger and Patricia Weiss

    FRANKFURT, Feb 18 (Reuters) - A therapy mix including Bayer's Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, prompting the drugmaker to boost sales estimates for the product.

    Nubeqa, when combined with standard therapy, reduced the risk of dying during the trial period by 32.5% in a comparison to standard therapy alone, the German company said in a statement on Thursday, citing trial results.

    As a result, Bayer said it now expected more than 3 billion euros ($3.4 billion) in sales from the product in its best year, up from a previous target of more than $1 billion, making Nubeqa the most promising growth driver at Bayer's drugs division.

    Nubeqa, also known as darolutamide, is jointly developed with Finnish drugmaker Orion and the partner company's stock soared 22.7% at the 0800 GMT market open, while Bayer shares gained 1.9%.

    Bayer, which is paying billions to settle U.S. claims its Roundup weedkiller caused cancer, needs to strengthen its drug development pipeline as its two pharmaceutical best-sellers, stroke prevention pill Xarelto and eye drug Eylea, face a decline in sales in a few years.

    Nubeqa is already approved in non-metastatic prostate cancer that cannot be treated with standard hormone therapy, and the new results point to a larger market opportunity if regulators clear the wider use.

    The drug is one of three Bayer pharmaceuticals that the company expects to generate more than $1 billion in peak annual sales, known in the industry as blockbusters, alongside kidney disease treatment finerenone and menopausal symptoms relief elinzanetant.

    The trial's overall success was announced in December and detailed results were published in The New England Journal of Medicine on Thursday.

    ($1 = 0.8797 euros)

    (Editing by Miranda Murray. Editing by Jane Merriman)

    ((ludwig.burger@thomsonreuters.com; +49 30 220133634))
  14. forum rang 7 4finance 18 februari 2022 20:05
    quote:

    stockholder schreef op 18 februari 2022 19:17:

    Het leek een mooie dag te worden voor de koers van Bayer. Helaas zakt de hele handel vanmiddag weer terug.
    We kunnen wel constateren dat de ondertoon voor Bayer goed is. Beloofd wat voor de cijfers op 1 maart as
    Ik heb net voor het sluiten flink bijgekocht door een andere long positie te verkopen. BAYER staat aan de vooravond van een periode van stijgen met al deze goede berichten.

  19. forum rang 7 4finance 22 februari 2022 16:47
    quote:

    N audio schreef op 22 februari 2022 09:14:

    Ik heb niet op mijn handen gezeten.
    Stukje verlies genomen op een klein deel van de porto. Dit deel vanochtend omgezet bij opening in Bayer.
    Ik ben wel benieuwd naar de cijfers.

    Mooi! Bayer zou toch flink moeten herstellen met alle positieve berichten.
    Eerst maar eens de €60 grens opzoeken.

  20. forum rang 4 stockholder 22 februari 2022 16:55
    quote:

    N audio schreef op 22 februari 2022 09:14:

    Ik heb niet op mijn handen gezeten.
    Stukje verlies genomen op een klein deel van de porto. Dit deel vanochtend omgezet bij opening in Bayer.
    Ik ben wel benieuwd naar de cijfers.

    Soms moet je inderdaad de bakens verzetten. Hoort bij een goede handelsgeest
475 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 24 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 875,15 +1,00%
EUR/USD 1,0656 +0,04%
FTSE 100 8.068,82 +0,56%
Germany40^ 18.058,80 +1,11%
Gold spot 2.302,47 -1,06%
NY-Nasdaq Composite 15.451,31 +1,11%

Stijgers

VIVORY...
+30,53%
PROSUS
+3,89%
ALLFUN...
+3,60%
JUST E...
+3,25%
BAM
+2,63%

Dalers

RANDST...
-5,96%
Akzo N...
-5,05%
NSI
-3,67%
FASTNED
-3,10%
Arcelo...
-1,37%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!